Sanofi Share Price LIQUIDNET SYSTEMS

Equities

SAN

FR0000120578

Pharmaceuticals

Delayed LIQUIDNET SYSTEMS 5-day change 1st Jan Change
- EUR -.--% Intraday chart for Sanofi -.--% -.--%

Financials

Sales 2024 * 46.35B 49.65B 3,929B Sales 2025 * 49.8B 53.34B 4,222B Capitalization 112B 120B 9,532B
Net income 2024 * 7.08B 7.59B 600B Net income 2025 * 8.69B 9.31B 737B EV / Sales 2024 * 2.58 x
Net Debt 2024 * 6.99B 7.49B 593B Net Debt 2025 * 2.37B 2.54B 201B EV / Sales 2025 * 2.31 x
P/E ratio 2024 *
16.2 x
P/E ratio 2025 *
13 x
Employees -
Yield 2024 *
4.3%
Yield 2025 *
4.53%
Free-Float 87.13%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 56 31/08/19
Chief Operating Officer 40 31/12/21
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 30/04/14
Director/Board Member 62 27/04/20
Director/Board Member 64 21/05/20
More insiders
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.94 EUR
Average target price
107.9 EUR
Spread / Average Target
+19.93%
Consensus